Evolving Role of Molecular Pathways in the Treatment of Relapsed Follicular Lymphoma in Individualized Care

View Activity

PROGRAM CHAIR & FACULTY

Nirav Shah, MD, MSHP
Assistant Professor of Medicine
Division of Hematology/Oncology
Medical College of Wisconsin
Milwaukee, WI

PROGRAM OVERVIEW

This online activity will review newly approved and investigational agents and combinations of agents that may improve outcomes for patients with relapsed, refractory follicular lymphoma (FL). Traditionally, FL has been associated with the development of aggressive disease and poor outcomes for many patients. The ongoing development of new compounds with unique mechanisms of action extends the available treatment options for patients across all lines of therapy, with an emphasis on personalization of care.

TARGET AUDIENCE

This CME initiative is focused on oncologists, hematologists, and oncology nurses but also is designed in a manner that makes the content applicable to other healthcare practitioners involved in the diagnosis, treatment, and management of FL.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Describe the carcinogenic pathways that support the pathogenesis of follicular lymphoma
  • Discuss the current treatment guidelines for relapsed follicular lymphoma and their application to
    clinical practice
  • Review the clinical trials data for newly approved therapies in relapsed follicular lymphoma and their
    mechanisms of action on carcinogenic pathways

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with
follicular lymphoma. CNE Credits: 1.5 ANCC Contact Hour
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Shah conducts research for Latisa Technology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Cathy Herbert, Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved
indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 14, 2019

EXPIRATION DATE: January 14, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.